Last reviewed · How we verify

NCT06933836

DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma

Recruiting now Last updated 18 April 2025
What this trial tests

trial testing DSLT enables newly diagnosed patients to remain well controlled and off medications in Open Angle Glaucoma (OAG) in 55 participants. Currently enrolling.

Timeline
31 March 2025
Primary endpoint
30 November 2027
31 December 2027

Quick facts

Lead sponsorBarnet Dulaney Perkins Eye Centers
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment55
Start date31 March 2025
Primary completion30 November 2027
Estimated completion31 December 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Barnet Dulaney Perkins Eye Centers

Who can join

30 and older, any sex, with Open Angle Glaucoma (OAG). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

DSLT demonstrates a ≥ 20% reduction of IOP from pre-treatment baseline in POAG patients naïve of previous glaucoma treatment at 12 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Open Angle Glaucoma (OAG)

Currently open trials in the same condition.

Other Barnet Dulaney Perkins Eye Centers trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06933836.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing